Add to MyYahoo RSS

Pharmaceutical News

Pharmaceuticals news continually updated from thousands of sources around the net.

1 hr ago | Business Wire

View Press Release

The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player.


Related Topix: Biotech, Medicine, Akorn, Healthcare Industry, HiTech Pharmacal Co, Marketing, Somerset, NJ

5 hrs ago | Mail & Guardian

The science behind dietary supplements

From multivitamins to fish oil, daily pills and powders have become routine for millions around the world.


Related Topix: Supplement, Fish Oil, Biotech, D and K Healthcare Resources, Medicine, Healthcare Industry, Nutrition, EPA, DHA

9 hrs ago | BioSpace

IMPAX Laboratories, Inc. Launches Authorized Generic RENVELA

RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.


Related Topix: Biotech, Impax Laboratories, Medicine, Healthcare Industry, Startups, Renagel, Sevelamer (generic), Healthcare Law, Food and Drug Administration, Law, Marketing

Wed Apr 16, 2014


Mylan Launches First Generic Ortho Evra Patch

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE , the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA * .


Related Topix: Biotech, Medicine, Mylan Laboratories, Healthcare Industry, Dey, Startups, Ortho Evra, Norelgestromin/Ethinyl Estradiol (generic), Food and Drug Administration


Jackson Puts Statewide Drug Take-Back Legislation on Hold

State Sen. Hannah-Beth Jackson , D-Santa Barbara, announced on Wednesday that, due to a lack of support from some of her legislative colleagues in the Senate Business, Professions and Economic Development Committee, she is shelving a bill this year to create the nation's first statewide drug take-back program for prescription and over-the-counter ... (more)


Related Topix: Santa Barbara, CA, Alameda County, CA

Impax Laboratories Receives New Coverage from Analysts at Sterne Agee

Other equities research analysts have also recently issued reports about the stock.


Related Topix: Biotech, Impax Laboratories, Medicine, Healthcare Industry, Startups

Sterne Agee Initiates Coverage on Teva Pharmaceutical Industries Ltd

The firm set a "neutral" rating on the stock. TEVA has been the subject of a number of other recent research reports.


Related Topix: Biotech, Teva Pharmaceutical Industries, Medicine, Healthcare Industry

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating )--Research and Markets has announced the addition of the "Global Testicular Cancer Drugs Market 2014-201... )--Research and Markets has announced the addition of the "Global ... (more)


Related Topix: Biotech, Teva Pharmaceutical Industries, Medicine, Cephalon, Healthcare Industry, SAS, Functional, Inc, Cameras

Parliament clears a 3 billion EU medicines R&D initiative

The European Parliament voted in favour of the second Innovative Medicines Initiative on Tuesday , a multi-billion Euro research programme run jointly by the European Commission and the pharmaceutical industry.


Tue Apr 15, 2014

Samsung Pharmaceutical Industry Corporation Limited (001360) -...

The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.


Sys-Con Media

Repligen Corporation Set to Join the S&P SmallCap 600

S&P SmallCap 600 constituent Akorn Inc. is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.


Related Topix: Repligen, Biotech, Medicine, Healthcare Industry, HiTech Pharmacal Co, Akorn, Financial Markets

The Motley Fool

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Does Merck stand a chance? Merck has lagged the hepatitis C race, but the phase 2 results from its oral combination of MK-5172 and MK-8742 in genotype 1 patients are quite impressive.


Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Bristol Myers Squibb, Bloomsbury Publishing, Publishing, Media, Medarex, Bristol-Myers Squibb

Sys-Con Media

Mylan Launches Generic LunestaA Tablets

Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of insomnia.


Related Topix: Biotech, Medicine, Mylan Laboratories, Healthcare Industry, Dey, Startups, Food and Drug Administration

Sys-Con Media

Partnership Renewals, Earning Results Releases, Monthly Sales Data,...

Today, Analysts Review released its analysts' notes regarding CSX Corp. , Cardinal Health, Inc. , L Brands, Inc. , Discovery Communications, Inc. and CH Robinson Worldwide Inc. .


Related Topix: Biotech, CSX, Railroads, Medicine, Healthcare Industry, Cardinal Health, Incentive Solutions, Allegiance, Transportation, Logistics, CH Robinson Worldwide


Steering a company in a new direction

EBay chief executive John Donahoe knew something was up when his firm's security team advised him not to attend a conference for sellers on safety grounds.

1 comment

Related Topix: eBay, Startups, Biotech, Medicine, Healthcare Industry, Cardinal Health

Mon Apr 14, 2014

P&T Community

New Drug Application Submitted to FDA for Fixed-Dose Atazanavir/Cobicistat Combo for HIV-1 Patients

A new drug application has been submitted to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz , and cobicistat , an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain human immunodeficiency virus-1 medications in the blood and make them more ... (more)


Related Topix: Health, HIV/AIDS, Reyataz, Atazanavir Sulfate (generic), Law, Healthcare Law, Bristol Myers Squibb, Biotech, Bloomsbury Publishing, Media, Publishing, Medicine, Healthcare Industry


UPDATE 1-Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions

Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.


Related Topix: Biotech, Medicine, HiTech Pharmacal Co, Healthcare Industry, Watson Pharmaceuticals

Burlington Times News

At least one hurt in Winston-Salem lab explosion

Police, firefighters and emergency personnel responded to a call about 10 a.m. Monday.


Related Topix: Explosion

Sys-Con Media

RelayHealthA Earns Omega NorthFace ScoreBoard Award

Today RelayHealth Financial a announced it has received the NorthFace ScoreBoard AwardSM in recognition of excellence in customer service and support for its RelayAssurancea and RelayClearancea revenue cycle management solutions.


Related Topix: Startups, RelayHealth, Biotech, Medicine, McKesson, Household Products, Healthcare Industry

Sys-Con Media

Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys

The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months.


Related Topix: Startups, Medivation, Biotech, Medicine, Athersys, Healthcare Industry, Financial Markets, Achillion Pharmaceuticals


Pharmaceuticals Jobs